Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company pioneering in the development and commercialization of fully human polyclonal antibodies using its proprietary DiversitAb™ platform. Unlike traditional methods involving human plasma or serum, SAB leverages genetically engineered transchromosomic cattle (Tc Bovine™) to produce large volumes of human antibodies (immunoglobulin G) in response to specific antigens.
The company's core technologies aim to provide novel therapies for a wide range of immune and autoimmune disorders, including its lead asset SAB-142, which targets type 1 diabetes (T1D). SAB-142 is a human anti-thymocyte immunoglobulin designed to modulate the body's immune response, potentially delaying the onset and progression of T1D. This innovative approach has shown promise in early clinical trials, with Phase 1 studies demonstrating safety and biological activity without the adverse reactions commonly associated with animal-derived therapies.
Recent achievements include the FDA granting Breakthrough Therapy and Fast Track Designations to SAB-176, a fully human polyclonal antibody targeting multiple strains of Influenza A and B. This reflects the potential of SAB's platform to address unmet medical needs swiftly and effectively.
SAB is actively pursuing multiple projects and partnerships to expand its clinical pipeline. Notable collaborations include a pharmacokinetic and safety study for SAB-176, conducted in partnership with the Henry Jackson Foundation and the NMRC Clinical Trials Center. Additionally, SAB’s ongoing Phase 1 clinical trial for SAB-142 has successfully completed dosing the third cohort with no observed serum sickness.
Financially, SAB reported positive results for Q1 2024, with sufficient cash reserves expected to fund operations into 2026, assuming the exercise of outstanding Tranche B warrants. The company's strategic relocation of its headquarters to Miami, FL, and the recent appointment of Dr. Jay Skyler to its Board of Directors underscore its commitment to T1D research and treatment.
SAB Biotherapeutics continues to engage with the scientific and investment communities, providing regular updates on its progress and maintaining transparency in its forward-looking statements. As a pioneer in biopharmaceutical innovation, SAB is poised to make significant contributions to the treatment of immune and autoimmune disorders.
SAB Biotherapeutics (Nasdaq: SABS, SABSW) announced that its co-founder and CEO, Dr. Eddie Sullivan, will present at the 2023 BIO CEO & Investor Conference in New York City from February 6-9. The presentation will feature SAB's proprietary DiversitAb™ platform, which uniquely produces fully-human polyclonal antibodies without human donors. Dr. Sullivan emphasized the importance of developing therapies for viral infections like COVID-19 and influenza and highlighted progress in treating autoimmune disorders. Interested parties can schedule meetings through the BIO One-on-One Partnering system.
SAB Biotherapeutics (SABS) has received an additional $8.2 million from the U.S. Department of Defense, raising the total amount to $16.8 million since November 2022, related to the closeout of a discontinued COVID-19 contract. The contract was originally awarded in 2019 but was terminated in August 2022 due to misalignment with government requirements. CEO Eddie Sullivan noted that this funding validates SAB's antibody platform, which is moving to Phase 3 development for various medical programs, including Influenza and Type 1 Diabetes. The company expects sufficient cash flow to fund operations through 2023.
SAB Biotherapeutics (SABS) announced the successful completion of a GLP-tox study for SAB-142, its fully-human polyclonal therapeutic aimed at delaying type 1 diabetes onset. The study demonstrated SAB-142's well-tolerated profile at various doses and its pharmacodynamic effects compared to FDA-approved treatments. The company plans to file an IND within 12 months. SAB-142's development marks a significant milestone, potentially offering a safer treatment option for patients by reducing immune-related adverse reactions commonly seen with animal-derived therapies.
SAB Biotherapeutics (Nasdaq: SABS) announced that Dr. Alexandra Kropotova will present at the Biotech Showcase in San Francisco on Jan. 10, 2023. Her presentation will focus on SAB's innovative DiversitAb™ platform, which develops fully-human polyclonal antibodies using transchromosomic cows, offering potential treatments for complex diseases like influenza and type 1 diabetes. The company emphasizes its commitment to addressing multiple disease targets simultaneously, showcasing promising data from clinical trials that indicate long-lasting efficacy against various pathogens.
SAB Biotherapeutics (SABS) announced promising results from a collaboration with CSL, confirming that its DiversitAb™ platform can produce fully-human anti-idiotype polyclonal antibodies. These findings demonstrated the potential to target and neutralize autoantibodies linked to autoimmune diseases, such as neuromyelitis optica. The platform effectively developed treatments that bind to harmful autoantibodies without broad immunosuppression, indicating significant therapeutic implications for various autoimmune disorders. SAB aims to provide effective treatment options for patients affected by these diseases.
SAB Biotherapeutics (Nasdaq: SABS, SABSW) has been chosen to present at the Biotech Showcase 2023 from January 9-11 in San Francisco. Dr. Alexandra Kropotova will deliver a presentation on January 10, focusing on the company's unique DiversitAb™ platform, which generates fully-human polyclonal antibodies without human donors. This platform shows promise against various pathogens, including influenza and Clostridioides difficile. The conference will also facilitate networking opportunities with potential partners and investors.
SAB Biotherapeutics has announced a successful private placement, raising approximately $7.9 million by selling around 7.3 million shares of common stock and warrants. This transaction, which closed on December 7, 2022, attracted existing and new institutional investors, including noted biotech investor T. Denny Sanford. The warrants, priced at $1.08, will be exercisable in six months and expire in five years. Funds raised will support SAB's immunotherapy pipeline targeting Clostridioides difficile and type 1 diabetes, along with general corporate purposes.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q3 2022 financial results, highlighting developments in its immunotherapy pipeline. The company secured $8.6 million from its DoD contract and expects operational funding to last until July 2023. However, cash reserves fell to $8.3 million from $16.6 million, due to a $7.1 million operating loss. R&D expenses decreased to $7.4 million compared to $15.1 million last year. The net loss was $7.1 million, consistent with the previous year's loss of $4.1 million. SAB plans to advance its anti-influenza and C. diff therapeutic candidates significantly.
SAB Biotherapeutics (SABS) will present at the U.S. Pharma Partnering Summit on Nov. 17-18, 2022, in Boston, MA. Co-Founder and CEO Eddie Sullivan will discuss the company's DiversitAb™ platform and its promising therapeutics, including SAB-176 for influenza, SAB-195 for C. diff, and SAB-185 for COVID-19, during the presentation titled “Novel Biologic Therapeutics for Infectious Diseases.” The summit aims to enhance networking and deal-making within the biopharmaceutical industry, aligning with SAB's goals for innovation in immunotherapy.
SAB Biotherapeutics presented data on its polyclonal antibodies, SAB-176 for influenza and SAB-185 for COVID-19, demonstrating significant efficacy against highly mutating viruses at the 2022 Plasma Product Biotechnology Conference. The DiversitAb™ platform allows production of human antibodies without needing blood donations, enhancing safety and potency. Phase 2 results indicate SAB-185 effectively neutralizes multiple SARS-CoV-2 variants, while SAB-176 significantly reduced viral loads in H1N1 challenged adults, supporting its potential in treating respiratory diseases.
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?
What is the market cap of SAB BIOTHERAPEUTICS (SABS)?
What is SAB Biotherapeutics, Inc.?
What is the DiversitAb™ platform?
What is SAB-142?
What recent achievements has SAB Biotherapeutics reported?
Who are SAB's key partners?
Where is SAB Biotherapeutics headquartered?
What is the financial outlook for SAB Biotherapeutics?
How does SAB-142 differ from rabbit-derived ATG?
What is the focus of SAB's current clinical trials?
How can I learn more about SAB Biotherapeutics?
